Return to homepagePandemic Pact

Harnessing immunity for optimal SARS-CoV-2 and influenza vaccines

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: 2007929

Grant search

Key facts

  • Disease

    COVID-19, Unspecified

  • Known Financial Commitments (USD)

    $1,149,327.84

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    Dr. Sophie Valkenburg

  • Research Location

    Australia

  • Lead Research Institution

    University of Melbourne

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Vaccines are our most important public health measure to combat infection, however the optimal vaccine format and dosing, or duration of immunity towards influenza virus and SARS-CoV-2 is poorly understood. We need to pre-arm our immune system against antigenic drift and future outbreak strains. This proposal will determine the protective potential of broadly-reactive immune responses by current vaccines, recovered patients, and experimental vaccines for influenza viruses and SARS-CoV-2.